Promazine

NERVOUS SYSTEM

Key facts

Promazine is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1956. DrugCentral lists 40 molecular targets, including HRH1, ADRA1D and Adra1b. Recorded indications include Acute intermittent porphyria, Allergic conjunctivitis, Allergic rhinitis and Angioedema.

• Approval status: ofm (first approved 1956 by the FDA).
• Molecular targets: HRH1, ADRA1D, Adra1b and ADRA1A (40 listed in DrugCentral).
• Indications: Acute intermittent porphyria, Allergic conjunctivitis, Allergic rhinitis, Angioedema and Bipolar affective disorder, current episode manic and others.
• ATC code: N05AA03 (Phenothiazines with aliphatic side-chain).
• Molecular formula: C17H20N2S; molecular weight 284.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (21)

• Acute intermittent porphyria
• Allergic conjunctivitis
• Allergic rhinitis
• Angioedema
• Bipolar affective disorder, current episode manic
• Dermatographic urticaria
• Disruptive behavior disorder
• General anesthesia
• Intractable Hiccups
• Itching of skin
• Nasal congestion
• Nasal discharge
• Nausea
• Nausea and vomiting
• Pre-Op Apprehension
• Psychotic disorder
• Schizophrenia
• Sneezing
• Tetanus Adjunct Treatment
• Urticaria
• Vomiting

Contraindications (40)

• Acute disease of cardiovascular system
• Alcoholism
• Anemia
• Angina pectoris
• At risk for aspiration
• Benign prostatic hyperplasia
• Bradycardia
• Breastfeeding (mother)
• Carcinoma of female breast
• Chronic disease of respiratory system
• Chronic heart failure
• Coma
• Conduction disorder of the heart
• Congenital long QT syndrome
• Disease of liver
• Epilepsy
• Extrapyramidal disease
• Glaucoma
• Hyperglycemia
• Hyperprolactinemia
• Leukopenia
• Metabolic syndrome X
• Myocardial infarction
• Myocardial ischemia
• Neuroleptic malignant syndrome
• Neutropenic disorder
• Obesity
• Organophosphate poisoning
• Orthostatic hypotension
• Parkinsonism
• + 10 more

Mechanism & targets

Molecular targets (40)

Target	Gene	Action	Activity
Histamine H1 receptor	HRH1	unknown	Ki 8.70
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 8.43
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 8.34
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 8.23
Alpha-1A adrenergic receptor	Adra1a	unknown	IC50 8.03
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 7.89
5-hydroxytryptamine receptor 2A	HTR2A	antagonist	Ki 7.80
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 7.43
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 7.38
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 7.34
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 7.34
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 7.28
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 7.06
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 6.94
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.90
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 6.90
Dopamine receptor	DRD2|DRD1	unknown	IC50 6.89
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 6.83
D(3) dopamine receptor	DRD3	antagonist	Ki 6.80
D(2) dopamine receptor	DRD2	antagonist	Ki 6.70

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1956-04-13	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
N05AA03	NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Phenothiazines with aliphatic side-chain

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Sopor	1266.2
Drug abuse	617.3
Intentional self-injury	455.7
Suicide attempt	324.2
Intentional overdose	323.8
Electrocardiogram QT prolonged	144.6
Somnolence	142.7
Drug interaction	123.4
Bradyphrenia	118.3
Coma	111.9
Alcohol interaction	100.4
Hypotension	85.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Promazine is on its molecule page.

• Molecular formula: C₁₇H₂₀N₂S
• Molecular weight: 284.42 g/mol
• CAS number: 58-40-2
• InChIKey: ZGUGWUXLJSTTMA-UHFFFAOYSA-N
• PubChem CID: 4926

CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Promazine used for?

DrugCentral lists the following indications for Promazine: Acute intermittent porphyria, Allergic conjunctivitis, Allergic rhinitis, Angioedema, Bipolar affective disorder, current episode manic, Dermatographic urticaria, Disruptive behavior disorder and General anesthesia and others.

How does Promazine work?

Its molecular targets in DrugCentral include HRH1, ADRA1D, Adra1b and ADRA1A.

When was Promazine first approved?

Promazine was first approved by the FDA in 1956.

What is the chemical formula of Promazine?

Promazine has the molecular formula C17H20N2S and a molecular weight of 284.42 g/mol.

Sources

• DrugCentral drug card 2284 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200469 — compound record and bioactivity
• PubChem CID 4926 — chemical identifiers
• DrugBank DB00420 — drug record
• FDA UNII O9M39HTM5W — substance identity
• DailyMed: FDA labels for Promazine — current prescribing information (label search)
• UniProt P35367 (HRH1) — target protein
• UniProt P25100 (ADRA1D) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P23975 (SLC6A2) — target protein
• UniProt P28223 (HTR2A) — target protein
• UniProt P18825 (ADRA2C) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.